Semaglutide
GLP-1
Acts at the GLP-1 receptor pathway.
The future of metabolic medicine
Retatrutide Research and Emerging Weight-Loss Science
An educational review of an investigational triple hormone receptor agonist currently being evaluated in advanced clinical trials, published by Aevum Restorative Wellness in Houston.
Investigational - Not Currently Available
Important research and availability notice
Retatrutide remains investigational and is not FDA approved. It is not offered, prescribed, sold, administered, sourced, or reserved by Aevum Restorative Wellness. Current research findings do not guarantee future approval. Approved indications, commercial availability, pricing, warnings, contraindications, and prescribing information have not been established. This page is for general education only.
Retatrutide Research
GIP
GLP-1
Glucagon
Conceptual visualization of the three receptor pathways being studied
Investigational mechanism
Three receptor pathways within one research molecule
Retatrutide is being studied as a once-weekly molecule that activates receptors for GIP, GLP-1, and glucagon. Researchers are evaluating whether this combined signaling may influence appetite, satiety, energy intake, glucose regulation, energy expenditure, body weight, and broader cardiometabolic health.
These proposed effects remain under clinical investigation. A research mechanism should not be interpreted as proof of routine safety, effectiveness, or suitability for an individual patient. For treatment options available today, see medical weight loss in Houston.
- GIP A receptor pathway involved in glucose-dependent insulin signaling and metabolic regulation.
- GLP-1 A receptor pathway associated with appetite regulation, satiety, and glucose-dependent insulin signaling.
- Glucagon A receptor pathway being studied for its potential influence on energy expenditure and metabolic regulation.
Tirzepatide
GIPGLP-1
Acts at GIP and GLP-1 receptor pathways.
Retatrutide
GIPGLP-1Glucagon
Investigational activity at GIP, GLP-1, and glucagon receptor pathways.
Research evidence dashboard
What current studies have reported
Figures below are study-population averages and are not predictions or guaranteed individual outcomes. Select each study for context and limitations.
Peer-reviewed Phase 2 evidence
Phase 2 Obesity Trial
Adults with obesity or overweight without type 2 diabetes - 48 weeks
0.0%
Mean reduction at 48 weeks
highest studied dose
A randomized Phase 2 trial reported mean weight reduction of approximately 17.5% at 24 weeks and 24.2% at 48 weeks at the highest studied dose.
Gastrointestinal effects were the most commonly reported adverse events, were dose related, and were generally most noticeable during dose escalation. These findings supported development of the larger TRIUMPH Phase 3 program.
Sponsor-reported Phase 3 topline findings
TRIUMPH-4
Obesity or overweight with knee osteoarthritis, without diabetes - 68 weeks
0.0%
Mean reduction
12 mg investigational dose
Sponsor-reported topline findings showed mean weight reduction of up to approximately 28.7% at 68 weeks.
The study also reported improvements in knee-pain and physical-function measures. These findings do not establish that retatrutide is appropriate for every patient with osteoarthritis.
Sponsor-reported Phase 3 findings
TRIUMPH-1
Obesity or overweight with a weight-related condition, without diabetes - 80 weeks
0.0%
Mean reduction
12 mg investigational dose
Sponsor-reported findings showed average weight reduction of approximately 28.3% at 80 weeks with the 12 mg investigational dose.
In a prespecified extension involving participants with baseline BMI of at least 35, average reduction reached approximately 30.3% at 104 weeks. Additional study groups reported changes in knee-osteoarthritis pain and obstructive sleep-apnea severity.
These results are population averages and do not guarantee a particular individual outcome.
Sponsor-reported Phase 3 topline findings
TRANSCEND-T2D-1
Adults with type 2 diabetes - 40 weeks
0.0%
Mean weight reduction
12 mg investigational dose
Sponsor-reported findings showed average A1C reductions of up to approximately 2.0 percentage points at 40 weeks.
Participants receiving the highest investigational dose lost an average of approximately 16.8% of body weight. Weight reduction had not plateaued by the end of the reported treatment period.
Sponsor-reported Phase 3 topline findings
TRIUMPH-2
Obesity or overweight with type 2 diabetes - 80 weeks
0.0%
Mean reduction
12 mg investigational dose
Sponsor-reported findings showed average weight reduction of up to approximately 20.8% at 80 weeks.
A1C reductions reached up to approximately 1.6 percentage points in the reported efficacy results. Detailed peer-reviewed publication remained pending at the time of this review.
Sponsor-reported Phase 3 topline findings
TRIUMPH-3
Severe obesity with established cardiovascular disease, with or without diabetes - 80 weeks
0.0%
Mean reduction
12 mg investigational dose
Sponsor-reported findings showed average weight reduction of up to approximately 22.6% at 80 weeks.
Cardiovascular-event analyses were not definitive. Reported confidence intervals included the possibility of no benefit. The trial does not establish that retatrutide prevents heart attack, stroke, cardiovascular death, heart failure events, or other cardiovascular outcomes.
Safety and tolerability
Important questions remain under review
Commonly reported effects across studies included nausea, diarrhea, constipation, vomiting, reduced appetite, and other gastrointestinal symptoms.
- Side effects varied by dose and study population.
- Gastrointestinal effects frequently occurred during dose escalation.
- Some participants discontinued treatment because of adverse effects.
- Full approved prescribing information does not exist.
- Long-term risks, warnings, contraindications, and monitoring requirements remain subject to continuing research and regulatory review.
Current regulatory status
Not FDA approved
Research status last reviewed: July 26, 2026Retatrutide remains investigational in the United States and cannot be legally sold or marketed for routine human treatment.
Eli Lilly has announced plans to submit a U.S. Biologics License Application in the first quarter of 2027. A planned submission is not approval, and regulatory timing may change.
Medically reviewed by Xinwei Liu, MD, Medical Director. Regulatory status and trial data change over time; this page is reviewed on an ongoing basis and readers should confirm current status with primary sources.
Current treatment remains separate from future research
Aevum currently provides consultation for available medical weight-management options at our Houston Heights clinic, including physician-led tirzepatide treatment. Booking is not a retatrutide reservation, enrollment, prescription request, or waitlist. You can also review our lab-guided approach or membership pricing.
Explore Currently Available Medical Weight-Loss OptionsBegin with a thoughtful clinical conversation
Build a healthier relationship with weight, metabolism, and long-term care
Explore a physician-led medical weight-loss program in Houston designed around individualized treatment, clinical monitoring, realistic expectations, and sustainable metabolic health.
Physician-led
Clinical evaluation, individualized planning, and medical oversight.
Evidence-aware
Clear distinction between established care and emerging research.
Long-term focus
Metabolic health, body composition, monitoring, and maintenance.
Aevum Restorative Wellness
Personalized medical weight loss in Houston
Your consultation is an opportunity to discuss goals, relevant medical history, prior treatment experience, concerns, and currently available options. Care is guided by laboratory findings and clinical judgment rather than a standard protocol.
- Individualized clinical evaluation
- Laboratory assessment when clinically appropriate
- Personalized tirzepatide treatment planning
- Ongoing response and side-effect monitoring
- Nutrition, activity, and lean-mass considerations
- Long-term weight-management strategy
Prefer to speak with the clinic?
713-280-1551
Visit the clinic
Find us in Houston Heights
Aevum Restorative Wellness1224 Houston Avenue, Suite 101
Houston, TX 77007
Our clinic sits in Houston Heights, minutes from downtown Houston, River Oaks, Memorial, and the Texas Medical Center. Patients travel to us from across Greater Houston, and select follow-up visits are available through Aevum Mobile within our service radius.
The fastest way to start is through online booking. You can also reach the clinic by phone during business hours, or email care@aevumrestorative.com for general questions. Please do not send diagnoses, medication lists, or other sensitive medical details by email.
- Get driving directions to the clinic
- Contact Aevum Restorative Wellness
- Compare Aevum membership tiers
- Explore all Aevum services
- Meet Xinwei Liu, MD and the clinical team
Ready when you are
Book Your Consultation
Medical weight-loss treatment requires individualized clinical evaluation. Not every patient is a candidate for medication. Results vary, and no specific result is guaranteed. Potential medication risks and benefits should be reviewed with a qualified clinician, and treatment may require ongoing monitoring.
Pricing may vary according to treatment plan, dose, clinical needs, medication availability, and program participation. Pricing shown on this page is current as of August 2026. Scheduling a consultation does not guarantee medication eligibility, prescribing, treatment initiation, or insurance coverage.
Retatrutide remains investigational, is not FDA approved, and is not currently offered by Aevum Restorative Wellness. Website content is educational and does not replace individualized medical advice, diagnosis, or emergency care. For a medical emergency, call 911.
Medically reviewed by Xinwei Liu, MD, Medical Director. Last reviewed July 26, 2026.